Study of posaconazole with immunotherapy and chemo for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding posaconazole (an antifungal drug) to standard immunotherapy and chemotherapy before breast cancer surgery works better than just the standard treatment. It is for people with newly diagnosed, early-stage triple-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have just been diagnosed with triple-negative breast cancer for the first time.
- Your cancer is stage II or III (not stage I or IV).
- You are healthy enough for daily activities (ECOG score 0 or 1).
- You have not had breast cancer before or received radiation or systemic therapy for another cancer.
- You do not have an immune system disease or connective tissue disease, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.